TXG · 10x Genomics, Inc.

SAN DIEGO, Calif. — January 26, 2026 — BioTuring and 10x Genomics, Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a strategic collaboration to streamline and accelerate the path from data generation to biological insight for single cell and spatial research workflows. The collaboration connects 10x’s Chromium single cell platform and Xenium and Visium spatial platforms with BioTuring’s advanced analytical ecosystem. This integration supports more efficient exploration, visualization and interpretation of high-complexity single cell and spatial multiomics data by enabling a more seamless, end-to-end workflow that extends the downstream capabilities of 10x’s software ecosystem. As advances in single cell and spatial technologies enable larger and increasingly complex multimodal experiments, some researchers face challenges related to fragmented analysis workflows, access to scalable computational resources and analysis

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/ . The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions

10x Genomics, Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral blood samples from patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover immune signatures associated with disease activity, flare, remission and therapeutic response. The study will be led by investigators Kevin Wei, MD, PhD, Jeffrey Sparks, MD, MMSc, Deepak Rao, MD, PhD, Paul Hoover, MD, PhD and Abigail Schiff, MD, PhD, all from the Division of Rheumatology, Inflammation and Immunity at Brigham and Women's Hospital, founding member of Mass General Brigham. Autoimmune diseases remain among the most challenging conditions to diagnose and treat. Standard clinical tests provide only limited insight into the complex immune processes underlying these diseases and may be confounded by unrelated inflammation or

10x Genomics, Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care. The study with Dana-Farber intends to examine samples from hundreds of patients to evaluate therapeutic targets and relevant tumor microenvironment features for the most promising emerging therapies in oncology, including antibody-drug conjugates (ADCs), radioligand therapies (RLTs), bispecific antibodies, immune checkpoint inhibitors and other precision approaches. These treatments are reshaping the

10x Genomics, Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with the Cancer Research Institute (CRI) to advance the frontiers of immuno-oncology through high-resolution molecular data and AI. The multi-phase project will combine 10x's Chromium single cell and Xenium spatial platforms with advanced AI to build one of the world's most comprehensive translational and preclinical immuno-oncology datasets, spanning more than 20,000 samples, to reveal how the immune system recognizes and responds to cancer and to inform smarter treatment and prevention strategies for the future. The initiative will begin with a pilot phase, supported by leading researchers at some of the world's top immuno-oncology laboratories, including John Wherry, Ph.D. (University of Pennsylvania), Ansuman Satpathy, M.D., Ph.D. (Stanford University) and Andrea Schietinger, Ph.D. (Memorial Sloan Kettering Cancer Center). Together, they intend to generate approximately

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025. Preliminary, Unaudited Select Fourth Quarter 2025 Financial Results Revenue of approximately $166.0 million for the three months ended December 31, 2025, representing 11% growth sequentially and 1% growth compared to the corresponding prior year period. Instruments revenue of approximately $15.5 million, representing 29% growth sequentially and a 36% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $6.1 million of Single Cell instruments revenue, representing 24% growth sequentially and a 44% decrease year-over-year, and $9.4 million of Spatial instruments revenue, representing 32% growth sequentially and a 30% decrease year-over-year. Consumables revenue of approximately $141.7 million, representing 11% growth sequentially and a 6%

Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling Brisbane, CA – January 7, 2026 – CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development. CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this initiative, which aims to generate high-resolution maps